medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2019, Number 4

<< Back Next >>

Rev Invest Clin 2019; 71 (4)

Infectious Complications as a Predictor of Mortality in Patients with Non-Hodgkin Lymphoma Receiving Rituximab- Containing Chemotherapy

Meza-Meneses P, Cornejo-Juárez P, Vilar-Compte D, Volkow-Fernández P

Language: English
References: 16
Page: 275-282
PDF size: 176.43 Kb.


ABSTRACT

Background: Rituximab is a monoclonal antibody that increases the disease-free and overall survival of patients with non- Hodgkin lymphoma (NHL) CD20+. The objective of this study is to describe the prevalence and spectrum of infections in patients with NHL receiving rituximab-containing chemotherapy and the impact on survival. Materials and Methods: From January 2011 to December 2012, all patients diagnosed with NHL who received at least one dose of rituximab were included. Results: During the study period, 265 patients received rituximab; 108 (40.8%) males; the mean age was 60 ± 15 years. There were 177 infections in 85 patients, being the most common febrile neutropenia (n = 38; 21.5%) and mucosal barrier injury-related infections (n = 28; 15.8%). In 88 events (49%), there was a microbiologic diagnosis, being bacterial infection the most frequent (39.6%), but tuberculosis (TB) was developed in 4 cases (1.5%; incidence rate 721/100,000 person-year). During follow-up, 71 patients died (27%); in 35 cases, it was related to infection. There were no differences in follow-up between those who died due to infection versus those who died from another cause (p = 0.188). Multivariate analysis for mortality showed that age ›60 years, failure to achieve a complete response, and development of an infectious complication increased the risk of death. Conclusions: It is important to perform a screening test for TB in all patients who will receive rituximab and maintain a constant monitoring to detect an infectious process and begin treatment as soon as possible.


REFERENCES

  1. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC, et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9:36.

  2. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187-98.

  3. CTCAE Common Terminology Criteria for Adverse Events version 4.02. National Institute of Health. National Cancer Institute; 2009. Available from: https://www.evs.nci.nih.gov/ftp1/ C TC A E /A r c h i v e / C TC A E _ 4 . 0 2 _ 2 0 0 9 - 0 9 - 1 5 _ QuickReference_8.5x11.pdf. [Last accessed on 2016 Feb 03].

  4. See I, Iwamoto M, Allen-Bridson K, Horan T, Magill SS, Thompson ND, et al. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new national healthcare safety network definition. Infect Control Hosp Epidemiol. 2013;34:769-76.

  5. National Health Safety Network (NHSN) Surveillance Definitions: Central-Line Associated Bloodstream Infection (CLABSI) and Related Sites. Final 06_2006. Available from: http://www. msic-online.org/pdf/NHSN_Definitions_CLABSI.pdf. [Last accessed April 1, 2017].

  6. Tudesq JJ, Cartron G, Rivière S, Morquin D, Iordache L, Mahr A, et al. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmun Rev. 2018; 17:115-24.

  7. Alonso JJ, Cánovas A, Barreiro JG, Aguirre C. Infectious complications of chemotherapy in clinically aggressive mature B and T cell lymphomas. Eur J Intern Med. 2012;23:255-60.

  8. Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: serious adverse events associated with the use of rituximab-a critical care perspective. Crit Care. 2012;16:231.

  9. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15:e2-16.

  10. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol. 2009; 10:816-24.

  11. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53:1872-85.

  12. World Health Organization. Global Health Observatory Data Repository. Incidence Data by WHO Region. Number of Incident Tuberculosis Cases. Updated 07 Oct 2017. Available from: http://www.apps.who.int/gho/data/view. main.57036ALL?lang=en. [Last accessed on 2017 Nov 10].

  13. Castellanos-Joya M, Delgado-Sánchez G, Ferreyra-Reyes L, Cruz-Hervert P, Ferreira-Guerrero E, Ortiz-Solís G, et al. Results of the implementation of a pilot model for the bidirectional screening and joint management of patients with pulmonary tuberculosis and diabetes mellitus in mexico. PLoS One. 2014; 9:e106961.

  14. Zallio F, Limberti G, Ladetto M. Infections and follicular lymphoma: is there a link? Mediterr J Hematol Infect Dis. 2017; 9:e2017035.

  15. Dendle C, Gilbertson M, Spelman T, Stuart RL, Korman TM, Thursky K, et al. Infection is an independent predictor of death in diffuse large B cell lymphoma. Sci Rep. 2017;7:4395.

  16. Lanini S, Molloy AC, Prentice AG, Ippolito G, Kibbler CC. Infections in patients taking rituximab for hematologic malignancies: two-year cohort study. BMC Infect Dis. 2013;13:317.




2020     |     www.medigraphic.com